It was a successful quarter for the UK biotech sector, driven by a string of sizeable venture capital deals, initial public offerings and follow-on financings and the money has continued to roll in this week, with more funding for two innovative companies, NeRRe Therapeutics, Ltd. and MiNA Therapeutics.
Funding Boom Time Continues For UK Life Sciences
Accounted For 60% Of Biotech Venture Capital Invested In Europe
Nearly £1.6bn was invested in the pharma, biotech and life sciences sector in the UK from March to May, which means £2.39bn has been raised in the year to date, more than in the whole of 2020.
More from Financing
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
More from Business
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.